Header Logo

Connection

JOANNA YI to Neoplasm, Residual

Back to Details
This is a "connection" page, showing publications JOANNA YI has written about Neoplasm, Residual.
JOANNA YI
Connection Strength
0.047
Neoplasm, Residual
  1. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 03 20; 40(9):956-967.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.